(…) This Note proceeds in four Parts.
Part I examines the role of patents in drug development and the regulatory environment under the Hatch-Waxman Act.
Part II discusses ways in which follow-on patents can impede socially responsible licensing efforts by universities and other public-sector institutions.
Part III presents an empirical analysis of drug patent data, which shows that the number of patents per drug has increased over time, and examines factors that have influenced this trend. (…)
Part IV describes a table of detailed patent information for eighteen recently approved drugs with both public- and private-sector patents and discusses the implications of these results for university patenting and licensing. (…)
HOW MANY PATENTS DOES IT TAKE TO MAKE A DRUG? FOLLOW-ON
PHARMACEUTICAL PATENTS AND
Lisa Larrimore Ouellette
17 Michigan Telecommunications and Technology Law Review 299 (2010)